Vestal Point Capital »

Candel Therapeutics shares owned by Vestal Point Capital

Quarter-by-quarter ownership of Candel Therapeutics (CADL) shares owned by Vestal Point Capital from 13F filings

Historical chart of Vestal Point Capital investment in Candel Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Candel Therapeutics held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Candel Therapeutics by Vestal Point Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $5.5M 1.1M 4.90

More positions owned by Vestal Point Capital

Revolution Medicines (RVMD)
BioMarin Pharmaceutical (BMRN)
Abivax SA Sponsored Ads (ABVX)
Neurocrine Biosciences (NBIX)
Arrowhead Pharmaceuticals (ARWR)
Enliven Therapeutics (ELVN)
Repligen Corporation (RGEN)
Bicara Therapeutics (BCAX)
Nurix Therapeutics (NRIX)
Apogee Therapeutics (APGE)
Ascendis Pharma A/S Sponsored Adr (ASND)
Immunocore Holdings Ads (IMCR)
Taysha Gene Therapies Com Shs (TSHA)
Dyne Therapeutics (DYN)
Sanofi SA Sponsored Adr (SNY)

View all positions for Vestal Point Capital

Top funds holding Candel Therapeutics

FMR
BlackRock
Portolan Capital Management
Acorn Capital Advisors
Vanguard Capital Management
Vanguard Group
Vestal Point Capital
Millennium Management
Geode Capital Management
Halter Ferguson Financial
State Street Corporation
Sands Capital Ventures
Northern Trust
Vanguard Fiduciary Trust
Vanguard Portfolio Management

View all funds holding Candel Therapeutics